Basic implications of clinical observations: Venous thrombosis in the nephrotic syndrome

New England Journal of Medicine

Volumn 368, Issue 10, 2013, Pages 956-958

  Loscalzo, Joseph ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; PLASMINOGEN;

ARTICLE; DISEASE ASSOCIATION; FIBRINOLYSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOALBUMINEMIA; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; MORBIDITY; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOSIS; THROMBOPHLEBITIS; THROMBOSIS PREVENTION; THROMBUS; VEIN THROMBOSIS; GLOMERULUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMANS; KIDNEY GLOMERULUS; NEPHROTIC SYNDROME; PLASMINOGEN; VENOUS THROMBOSIS;

MLCS; MLOWN;

EID: 84874673057     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1209459     Document Type: Article

References (23)

1. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012;7:513-20.
2. Dickinson WH. On renal and urinary affections. New York: William Wood & Company, 1885:32.
3. Derow HA, Schlesinger MJ, Savitz HA. Chronic progressive occlusion of the inferior vena cava and the renal and portal veins. Arch Intern Med 1939;63:626-47.
4. Kendall AG, Lohmann RC, Dossetor JB. Nephrotic syndrome: a hypercoagulable state. Arch Intern Med 1971;127:1021-7.
5. Kauffmann RH, de Graeff J, Brutel de la Riviére G, Van Es LA. Unilateral renal vein thrombosis and nephrotic syndrome. Am J Med 1976;60:1048-58.
6. Huang F, Hutton L, Kalant N. Molecular sieving by glomerular basement membrane. Nature 1967;216:87-8.
7. Venkatachalam MA, Karnovsky MJ, Cotran RS. Glomerular permeability: ultrastructural studies in experimental nephrosis using horseradish peroxidase as a tracer. J Exp Med 1969;130:381-99.
8. Brenner BM, Hostetter TH, Humes HD. Glomerular perm-selectivity: barrier function based on discrimination of molecular size and charge. Am J Physiol 1978;234:F455-F460.
9. Robson AM, Giangiacomo J, Kienstra RA, Naqvi ST, Ingelfinger JR. Normal glomerular permeability and its modification by minimal change nephrotic syndrome. J Clin Invest 1974;54:1190-9.
10. Kauffmann RH, Weltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in nephrotic syndrome. Am J Med 1978;65:607-13.
11. Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984;144:1802-3.
12. Cosio FG, Harker C, Batard MA, Brandt JT, Griffin JH. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med 1985;106:218-22.
13. Singhal R, Brimble KS. Thromboembolic complications of nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006;118:397-407.
14. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994;46:287-96.
15. Machleidt C, Mettang T, Starz E, Weber J, Risler T, Kuhlmann U. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int 1989;36:1119-24.
16. Yoshida N, Aoki N. Release of arachidonic acid from human platelets: a key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 1978;52:969-77.
17. Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975;55:636-43.
18. Yashiro M, Muso E, Shio H, Sasayama S. Amelioration of hypercholesterolemia by HMG-CoA reductase inhibitor improved platelet hyperaggregability in nephrotic patients. Nephrol Dial Transplant 1994;9:1842-3.
19. Resh M, Mahmoodi BK, Navis GJ, Veeger NJ, Lijfering WM. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res 2011;127:395-9.
20. Thomson C, Forbes CD, Prentice CR, Kennedy AC. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 1974;43:399-407.
21. Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002;39:695-705.
22. Sraer JD, Kanfer A, Rondeau E, Lacave R. Glomerular hemostasis in normal and pathologic conditions. Adv Nephrol Necker Hosp 1988;17:27-55.
23. Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 2001;88:24-9.